-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Context Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q2 2024.
- Context Therapeutics Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.09M, a 41.6% increase year-over-year.
- Context Therapeutics Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$20M, a 0.69% decline year-over-year.
- Context Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$25.1M, a 63% decline from 2022.
- Context Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$15.4M, a 46.1% decline from 2021.
- Context Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$10.5M, a 309% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)